These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27579330)

  • 21. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
    Nell VP; Machold KP; Stamm TA; Eberl G; Heinzl H; Uffmann M; Smolen JS; Steiner G
    Ann Rheum Dis; 2005 Dec; 64(12):1731-6. PubMed ID: 15878904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).
    Kastbom A; Strandberg G; Lindroos A; Skogh T
    Ann Rheum Dis; 2004 Sep; 63(9):1085-9. PubMed ID: 15308517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
    Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
    Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Th17 and Th1 cells expressing CD161 are associated with disease activity in rheumatoid arthritis.
    Miao J; Zhang K; Lv M; Li Q; Zheng Z; Han Q; Guo N; Fan C; Zhu P
    Scand J Rheumatol; 2014; 43(3):194-201. PubMed ID: 24392804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis.
    Molad Y; Ofer-Shiber S; Pokroy-Shapira E; Oren S; Shay-Aharoni H; Babai I
    Eur J Clin Invest; 2015 Jun; 45(6):557-64. PubMed ID: 25832796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis.
    Nielen MM; van Schaardenburg D; Reesink HW; Twisk JW; van de Stadt RJ; van der Horst-Bruinsma IE; de Koning MH; Habibuw MR; Dijkmans BA
    Ann Rheum Dis; 2006 Apr; 65(4):535-7. PubMed ID: 16079166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased serum levels of tumor necrosis factor receptor-associated factor 1 (TRAF1) correlate with disease activity and autoantibodies in rheumatoid arthritis.
    Cheng T; Sun X; Wu J; Wang M; Eisenberg RA; Chen Z
    Clin Chim Acta; 2016 Nov; 462():103-106. PubMed ID: 27592369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis.
    Alexiou I; Germenis A; Ziogas A; Theodoridou K; Sakkas LI
    BMC Musculoskelet Disord; 2007 Apr; 8():37. PubMed ID: 17448247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease.
    Ramos-Remus C; Castillo-Ortiz JD; Aguilar-Lozano L; Padilla-Ibarra J; Sandoval-Castro C; Vargas-Serafin CO; de la Mora-Molina H; Ramos-Gomez A; Sanchez-Ortiz A; Avila-Armengol H; Aceves-Avila FJ
    Arthritis Rheumatol; 2015 Nov; 67(11):2837-44. PubMed ID: 26245885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
    El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
    J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
    Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
    Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum cytokine and periodontal profiles in relation to disease activity of rheumatoid arthritis in Japanese adults.
    Kobayashi T; Murasawa A; Komatsu Y; Yokoyama T; Ishida K; Abe A; Yamamoto K; Yoshie H
    J Periodontol; 2010 May; 81(5):650-7. PubMed ID: 20429644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.